

ForPatients

by Roche

Influenza

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Trial Status
Completed

Trial Runs In
7 Countries

Trial Identifier
NCT02623322 2016-000425-40
GV29893

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of MHAA4549A.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT02623322 2016-000425-40 GV29893
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 65 Years

Healthy Volunteers
No
